Given that a subset of patients with MDD exhibit elevated neuroinflammation39,40, NK1R antagonists with anti-inflammatory properties could be therapeutic candidates, particularly in patients with concurrent inflammatory conditions. Here, TACR1 is linked to major depressive disorder.